The area of immunotherapeutics for the treatment of metastatic castrate-resistant prostate cancer has made significant progress since the autologous cell-based vaccine sipuleucel T became the first and to date only immunotherapy for its treatment. This review focuses on a broad patent landscaping exercise of this therapeutic area and considers if basing this landscaping on key mechanisms of action is appropriate to elicit the main patenting trends.
Pharmaceutical patent analyst. 2017 Dec 11 [Epub ahead of print]
Invent, Dublin City University, Glasnevin, Dublin 9, Ireland.